Status:
COMPLETED
A Study of the Absorption of GT267-004 in Patients With Clostridium Difficile-Associated Diarrhea
Lead Sponsor:
Genzyme, a Sanofi Company
Conditions:
Pseudomembranous Colitis
Clostridium Difficile Diarrhea
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Approximately 24 patients will be entered into this study taking place in Canada. The aim of this study is to determine if an investigational drug is absorbed (taken up) in patients with C. difficile-...
Eligibility Criteria
Inclusion
- 18 years of age or older
- The presence of CDAD at the time of enrollment with no other likely etiology for the diarrhea
Exclusion
- \> 72 hours of treatment with metronidazole, vancomycin, or other antibacterial therapy specifically targeting the current acute episode of CDAD
- Patient not considered sufficiently stable clinically to complete the study period
Key Trial Info
Start Date :
September 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2007
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00382304
Start Date
September 1 2006
End Date
September 1 2007
Last Update
March 19 2015
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Edmonton, Alberta, Canada, T6G 2B7
2
Nanaimo, British Columbia, Canada, V9S 2B7
3
Vancouver, British Columbia, Canada, V3Z 1M9
4
Ottowa, Ontario, Canada, K1H 8L6